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Abstract
Introduction: Orthotopic liver transplantation (OLT) is accompanied by a significant postoperative infection risk.
Immunosuppression to prevent rejection increases the susceptibility to infections, mainly by impairing the adaptive
immune system. Genetic polymorphisms in the lectin complement pathway of the donor have recently been identified
as important risk determinants of clinically significant bacterial infection (CSI) after OLT. Another genetic factor
involved in innate immunity is NOD2, which was reported to be associated with increased risk of spontaneous
bacterial peritonitis in cirrhotic patients.
Methods: We assessed association of three genetic NOD2 variants (R702W, G908R and 3020insC) with increased
risk of CSI after OLT. 288 OLT recipient-donor pairs from two tertiary referral centers were genotyped for the three
NOD2 variants. The probability of CSI in relation to NOD2 gene variants was determined with cumulative incidence
curves and log-rank analysis.
Results: The R702W NOD2 variant in the recipient was associated with CSI after OLT. Eight out of 15 (53.3%)
individuals with a mutated genotype compared to 80/273 (29.3%) with wild type genotype developed CSI (p=0.027,
univariate cox regression), illustrated by a higher frequency of CSI after OLT over time (p=0.0003, log rank analysis).
Multivariate analysis (including the donor lectin complement pathway profile) showed independence of this R702W
NOD2 association from other risk factors (HR 2.0; p=0.04). The other NOD2 variants, G908R and 3020insC, in the
recipient were not associated with CSI. There was no association with CSI after OLT for any of the NOD2 variants in
the donor.
Conclusion: The mutated NOD2 R702W genotype in the recipient is independently associated with an increased
risk of bacterial infections after liver transplantation, indicating a predisposing role for this genetic factor impairing the
recipient’s innate immune system.
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Introduction
Results of liver transplantations have steadily improved over
the last decades with 5-years patient survival at 70%-80% in
recent years. This success is attributable to improved operative
techniques, earlier detection and treatment of post operative
complications and new immunosuppressive drugs [1].
However, infections still represent an important clinical problem
after orthotopic liver transplantation (OLT) with significant
patient morbidity and mortality [2]. There are several
contributing factors for this high infection risk, for example the
immunosuppressive agents that prevent rejection increase the
susceptibility to infections, mainly by interference with the
acquired immune system. In addition, previous studies showed
that genetic polymorphisms in the lectin complement pathway
of the donor also contributes significantly to the risk of infection
after liver transplantation [3,4]. With the current study we
assessed whether genetic polymorphisms in NOD2
(nucleotide-binding oligomerization domain containing 2), also
pivotal in the innate immunity, are associated with infectious
complications and mortality after OLT.
NOD2 is an intracellular receptor, recognizing bacterial
peptidoglycan, present in macrophages, dendritic cells and
certain intestinal epithelial cells, including paneth cells, that
play an important role in innate immunity [5–7]. Three genetic
NOD2 variants are known to be strongly associated with
Crohn’s disease [8,9]. The same NOD2 variants are also
involved in several infectious conditions: an increase in sepsis
related mortality in the ICU has been described [10] and
recently the occurrence of spontaneous bacterial peritonitis in
liver cirrhosis patients was reported to be increased among
NOD2-carriers and associated with reduced survival [11].
NOD2 was also found to be associated with increased risk of
graft versus host disease and transplant related mortality in
haematopoietic stem cell transplantation [12], and in kidney
transplantation mutated NOD2 haplotypes are associated with
higher rates of death with functioning graft [13].
Based on the above we hypothesized that genetic variants in
NOD2 could be associated with increased risk of bacterial
infections after liver transplantation, potentially leading to
impaired graft- and patient survival.
Methods
The study was approved by the Medical Ethics Committee
from the University Medical Center Groningen, the Netherlands
and the Medical Ethics Committee from the Leiden University
Medical Center, the Netherlands. From all patients written
informed consent was obtained, all in compliance with the
Helsinki Declaration
Study population
The study population consisted of 307 OLT recipient-donor
pairs. From both participating centers only those patients
whose DNA was available from both donor and recipient, and
who had at least 7 days of follow-up after liver transplantation
were included. 140 patients received OLT at the Leiden
University Medical Center (LUMC) in the Netherlands between
1992 and 2005, and 167 patients received OLT at the
University Medical Center Groningen (UMCG) in the
Netherlands between 2000 and 2005. The cohort has recently
been described in a previous study [4].
The LUMC patients received standard immunosuppressive
therapy consisting of corticosteroids, a calcineurin inhibitor (i.e.,
cyclosporine or tacrolimus) with or without mycophenolate
mofetil or azathioprine and/or basiliximab. The UMCG patients
received standard immunosuppressive therapy consisting of
basiliximab combined with a calcineurin inhibitor with or without
corticosteriods and/or mycophenolate mofetil. Until 2001
azathioprine was used instead of mycophenolate mofetil in
case of impaired renal function, and basiliximab on day 0 and 4
was introduced in 2001. All patients received 24 hours of
prophylactic antibiotics intravenously: gentamycin, cefuroxim,
penicillin G, and metronidazol in the LUMC, amoxicillin-
clavulanate and ciprofloxacin in the UMCG. In addition, the
LUMC patients received 3 weeks of selective digestive tract
decontamination (polymyxin/neomycin, norfloxacin, and
amfotericin B) after OLT. After surgery, all patients were
intensively monitored according to standardized protocols for
any infection, rejection, or poor function of the new liver. After
hospital discharge, frequent regular visits and standard
procedures in case of suspicion of an infection after OLT,
including additional visits upon febrile temperature, are
operational in both transplant centers.
Clinical Variables
The general patient database, original patient reports,
transplantation databases, and microbiology records were
evaluated to identify episodes of clinical and laboratory-
confirmed bacterial infections within the first year after
transplantation. The identified infections were considered
clinically significant bacterial infections (CSI) when they
complied with the Centers for Disease Control and Prevention
criteria for diagnosing infection [14]. All infections found were
categorized into sepsis (including symptomatic urinary tract
infection - urosepsis), pneumonia; and intra-abdominal
infections, i.e., cholangitis and peritonitis.
Demographic and clinicopathological characteristics of the
recipient at the time of OLT (age, sex, indication for liver
transplantation, Child-Pugh classification, and laboratory Model
for End-Stage Liver Disease [MELD] score), donor information
(age, sex), and posttransplant follow-up data
(immunosuppressive regimen, acute cellular rejection
according to the Banff scheme [15]) were also collected from
the transplantation databases. Clinical characteristics of donors
and recipients are shown in Table 1.
Genotyping of the NOD2 variants
Genomic DNA was extracted routinely from peripheral blood
and/or tissue samples.
All donors and recipients were genotyped for the NOD2
SNPS rs2066844 (R702W), rs2066845 (G908R), and
rs2066847 (frame-shift mutation 1007fs, or 3020insC) by
means of Applied Biosystems Taqman (ABI 7900 HT)®
technology according to the manufacturer’s recommendations
at the Laboratory of Genetics at the UMCG in January 2012.
NOD2 and Infections after Liver Transplantation
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For rs2066844 and rs2066845 pre-made assays were provided
by applied biosystems (AB ID:C_11711717468_20 and AB ID
C_11717466_20 respectively). The genotyping assay for
rs2066847 was custom developed by Applied Biosystems
(forward primer GTCCAATAACTGCATCACCTACCT; reverse
primer CAGACTTCCAGGATGGTGTCATTC; VIC-labeled MGB
probe CAGGCCCCTTGAAAG; FAM-labeled MGB probe
CAGGCCCTTGAAAG).
The results of the genotyping assay were analyzed using the
SDS 2.3 software compatible with the Applied Biosystems
Taqman®. Results obtained from SDS were exported to excel
and SPSS for further statistical analyses.
Table 1. Characteristics of all Eligible Orthotopic Liver
Transplant Recipients and Donors in the Study (N=307).
Variable  
Age (median, IQR)  
Recipient 51 (41-56)
Donor 46 (34-55)









Other disease§ 123 (40.1)




Lab MELD score (median, IQR) 15 (11-21)
Donor-type, N (%)  
Donation after cardiac death 24 (7.8)
Donation after brain death 283 (92.2)
Maintenance immunosuppression, N (%)  
Prednisone / CNI / basiliximab (+ MMF) 206 (67.1)
Prednisone / CNI (+ azathioprine) 101 (32.9)
Acute cellular rejection, N (%)  
Yes 107 (34.9)
No 200 (65.1)




IQR denotes interquartile range; MELD, Model for End-Stage Liver Disease; CNI,
calcineurin inhibitors; MMF, mycophenolate mofetil; LCBI, laboratory-confirmed
bloodstream infection; PNEU, pneumonia; IAB, intra-abdominal infection.
§ Other diseases included predominately autoimmune hepatitis, cryptogenic
cirrhosis and metabolic disorders.
Statistical analysis
Associations between baseline characteristics of the liver
transplant recipients, donors, and posttransplant follow-up data
and CSI were performed with the use of univariate Cox
regression models. The probability of clinically significant
infection within the first year after transplantation in relation to
NOD2 gene variants was determined with cumulative incidence
curves using Kaplan-Meier analysis, and the differences
between groups were assessed by log-rank test. Patients were
censored at the date of the last follow-up, death, or liver
retransplantation. The multivariate Cox proportional hazards
regression analysis was used to evaluate the independence of
the potential association of R702W, G908R and 3020insC with
infection. Factors associated with infection with a P value of
less than 0.15 in the univariate analysis were entered in the
multivariate model and non-significant factors were removed by
means of a backward-selection procedure. In this multivariate
analysis it was also assessed whether associations were
independent from previously described associated genetic
lectin pathway variants in the donor [4]. Results were
considered statistically significant when P values were <0.05.
Bonferroni correction for the number of SNPs tested was not
performed because SNPs were selected on the basis of a
deducible hypothesis. All analyses were performed with the
SPSS statistical software package (version 16.02; SPSS, Inc.,
Chicago, IL).
Results
Prevalence of NOD2 variants in recipients and donors
Overall more than 95% of all individuals were successfully
genotyped for the three NOD2 variants R702W (rs2066844),
G908R (rs2066845) and 3020insC (2066847). In individuals
with all variants successfully genotyped any NOD2 variant was
present in 39/287 (13.6%) of the recipients of an OLT and in
54/289 (18.7%) of the liver donors (p=0.15).
The minor allele frequency (MAF) in R702W was higher in
donors compared to recipients (5.1% and 2.8%, p=0.050). In
G908R MAF was 2.9% in recipients and 2.0% in donors
(p=0.35) and in 3020insC MAF was 1.2% in recipients and
2.2% in donors (p=0.18). Table S1 illustrates genotype
distribution for all three SNPs in recipients and donors stratified
for occurrence of CSI.
NOD2 variants in recipients and donors in relation to
infectious complications
R702W in the recipients, successfully determined in 288
cases, was significantly associated with the development of
infectious complications after liver transplantation. In recipients
with one or two risk alleles (genotype CT and genotype TT) for
R702W the CSI frequency was 53.3% (8 out of 15) as opposed
to 29.3% (80 out of 273) in recipients with the wildtype (CC)
genotype (HR 2.1, p = 0.03, univariate cox regression). The
development of a CSI over time was also significantly higher in
individuals with one or to mutated alleles in R702W (p < 0.001,
log rank analysis, Figure 1.). One recipient carrying the TT
genotype developed infection early after transplantation. When
grouping the two risk genotypes (CT and TT) together, the
NOD2 and Infections after Liver Transplantation
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association was borderline nonsignificant (p=0.070, univariate
cox regression; p = 0.063, log rank analysis; p=0.096 in
multivariate analysis). There was no significant relation
between site-specific infections (i.e., laboratory-confirmed
bloodstream infection, pneumonia or intra-abdominal infection)
and mutated alleles in R702W (data not shown).
The association of recipient NOD2 R702W showed the same
trend direction in both independent sub cohorts. In cohort 1 the
only individual with TT genotype and two out of six (33.3%)
individuals with CT genotype compared to 33 out of 151
(21.9%) individuals with CC genotype developed infection after
transplantation (p < 0.001, log rank analysis). In cohort 2 the
similar, although not statistically significant, trend was
observed, i.e., five out of eight (62.5%) individuals with CT
genotype developed infection after OLT compared to 47 out of
122 (38.5%) individuals with the CC genotype (p = 0.40, log
rank analysis).
In the other two NOD2 variants, G908R and 3020insC,
recipient genotypes were equally distributed between patients
that did or did not develop a CSI (p = 0.13 and p = 0.96
respectively). Regarding the donor genotypes there was no
significant association with the number of CSI after
transplantation for any of the three NOD2 variants (R702W p =
0.26, G908R p = 0.16, 3020insC p = 0.65; Table S1).
We also assessed whether there was a difference in
occurrence of CSI in individuals carrying one or more of either
NOD2 variants in the recipient or donor. Twelve out of 39
(30.8%) individuals with one or more NOD2 variant in the
recipient developed CSI compared to 76 out of 248 (30.6%)
individuals without recipient NOD2 variant (p = 0.97). Similarly,
Figure 1.  Development of clinically significant infection
over time in relation to the recipient NOD2 R702W
genotype.  Occurrence of clinically significant infection in days
after OLT in relation to the recipient NOD2 R702W genotype.
CC = wildtype, TT homozygote for mutation, CT =
heterozygote. The numbers below the Kaplan – Meier curves
represent the number of individuals ‘at risk’ per genotype at
particular time points after transplantation.
doi: 10.1371/journal.pone.0072617.g001
regarding the donor NOD2 status no difference was observed
in the occurrence of CSI: 14 out of 54 (25.9%) individuals with
one or more NOD2 variant in the donor developed CSI
compared to 70 out of 235 (29.8%) individuals without donor
NOD2 variant (p = 0.48)
Multivariate analysis
Based on the observed NOD2 association a multivariate
analysis was performed to assess whether the R702W risk
allele was a risk factor for the development of CSI independent
from recently described associations in the lectin pathway
donor profile and other potential risk factors. This analysis
showed that the association of the minor allele of NOD2
R702W in the recipient is indeed independent from the lectin
pathway profile of the donor and the only other significant
contributing factor, namely the gender of the recipient donor
pair (HR 2.0, p = 0.04; Table 2)
NOD2 variants in recipient and donor in relation to
patient survival
None of the NOD2 variants in donor or recipient was found to
be associated with patient survival the first year after OLT. In
total 27 patients deceased within one year after transplantation:
one recipient carried the R702W variant, two recipients carried
the G908R variant and two recipients carried the 3020insC
variant. R702W, G908R and 3020insC was present in five,
zero and one donor(s) respectively.
Discussion
In the current study it was found that the existence of the
NOD2 variant R702W in the recipient is associated with an
increased risk of bacterial infections after liver transplantation.
This association was found to be independent of clinical
variables, like gender, that are associated with increased
bacterial infections. Furthermore, this NOD2 R702W
association was shown to be independent of the previously
described infection risk mutations in the lectin complement
pathway of the donor liver [4].
Liver transplant recipients with one or two risk alleles for
R702W (genotype CT and genotype TT) in the recipient
developed more often a clinically significant infection, i.e.,
sepsis, pneumonia or abdominal infection, than individuals with
a wild type genotype. It is interesting to note that one individual
with homozygote TT risk for NOD2 R702W variant in the
recipient developed infection early after transplantation. The
recipients with heterozygote CT risk genotype developed
infection more than three months after transplantation. We
observed no association with NOD2 variants in recipient or
donor with patient survival in the first year after liver
transplantation.
The risk of infections after transplantation of a solid organ is
the resultant of the net state of an impaired immune defence.
Multiple factors contribute to the increased risk of infections,
including the outcome of transplantation with or without
technical complications, graft dysfunction and the intensity of
immunosuppression [16,17]. Genetic predisposition of recipient
and/or donor organ influencing the innate immune system is
NOD2 and Infections after Liver Transplantation
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likely to play a central role in further increasing the risk of
infection. For example, we recently reported that genetic
variants in the lectin complement pathway of the donor
increases the risk of CSI after transplantation. Components of
the lectin pathway of complement activation, including mannan
binding lectin 2 (MBL2), ficolin 2 (FCN2) and Mannan-binding
lectin serine protease 2 (MASP2), are primarily produced in the
liver. Therefore, functional SNPs in these polymorphic genes
present in the donor liver would lead to reduced complement
activation and opsonisation resulting in an increased infection
risk. We now show that the NOD2 R702W variant in the
recipient is another innate risk factor for bacterial infections
after OLT. NOD2 is a critical component of the intestinal
immunological barrier. In the initial period after transplantation
this intestinal barrier is already compromised due to the
postoperative state of the patient [18,19]. Furthermore,
Table 2. Univariate and Multivariate Analysis to Infection risk after orthotopic liver transplantation (N=288).
   Univariate   Multivariate  
Variable Bacterial infection % (N) HR CI (95%) P Value HR CI (95%) P Value
Age        
Recipient 30.6 (88/288) 0.99 0.98-1.0 0.37    
Donor 30.6 (88/288) 0.99 0.98-1.0 0.11    
Gender recipiënt    0.02   0.02
Male/male 40.8 (40/98) 2.6 1.4-5.0 0.004 2.6 1.4-5.0 0.004
Male/female 30.0 (15/50) 1.8 0.84-3.8 0.13 1.5 0.68-3.2 0.32
Female/male 27.6 (21/76) 1.6 0.79-3.3 0.19 1.5 0.71-3.0 0.30
Female/female 18.8 (12/64) ref   ref   
Primary liver disease    0.49    
Viral 37.5 (21/56) 1.5 0.86-2.6     
Alcoholic 26.3 (10/38) 1.1 0.52-2.1     
Cholestatic 33.3 (25/75) 1.3 0.77-2.2     
Other disease§ 26.9 (32/119) ref      
Child-Pugh class    0.14    
C 36.8 (35/95) 1.8 0.99-3.4 0.05    
B 30.0 (39/116) 1.4 0.76-2.6 0.29    
A 22.2 (14/63) ref      
Lab MELD score 31 (88/288) 1.0 0.97-1.0 0.72    
Donor-type        
Donation after cardiac death 37.5 (9/24) 1.3 0.65-2.6 0.47    
Donation after brain death 29.9 (79/264) ref      
Immunosuppression        
Prednisone/CNI/basiliximab (+ MMF) 28.1 (55/196) 0.74 0.48-1.1 0.18    
Prednisone/CNI (+ azathioprine) 35.9 (33/92) ref      
Acute cellular rejection        
Yes 24.0 (24/100) 0.60 0.38-0.95 0.03    
No 34.0 (64/188) ref      
CMV seropositivity    0.74    
D+/R+ 26.4 (23/87) 0.79 0.42-1.50 0.47    
D+/R- 30.8 (12/39) 0.95 0.45-2.01 0.89    
D-/R+ 32.5 (37/114) 1.1 0.59-1.90 0.85    
D-/R- 33.3 (16/48) ref      
Lectin complement pathway donor profile‡  1.8 1.4-2.3 <0.001 1.8 1.4-2.3 <0.001
3 variants 63.2 (12/19) 4.1 1.6-10.4 0.003 4.1 1.6-10.5 0.003
2 variants 39.8 (41/103) 2.5 1.1-5.5 0.03 2.3 1.0-5.1 0.047
1 variant 21.7 (28/129) 1.2 0.5-2.6 0.73 1.1 0.47-2.5 0.86
0 variants 18.9 (7/37) ref   ref   
Recipient R702W  2.1 1.1-4.2 0.03 2.0 1.0-4.0 0.040
TT 100 (1/1) 18.1 2.4-136.6 0.005    
CT 50.0 (7/14) 1.7 0.80-3.8 0.16    
CC 29.3 (80/273) ref      
HR denotes hazard ratio; CI, confidence interval; MELD, Model for End-Stage Liver Disease; CNI, calcineurin inhibitors; MMF, mycophenolate mofetil
‡The presence of donor-recipient genotypic groups associated with bacterial infections within the individual were clustered as lectin pathway donor profile; MBL2: XA/O and
O/O donor and A/A and YA/O recipient; FCN2: CT or TT donor and or recipient; MASP2: AA donor and or recipient
NOD2 and Infections after Liver Transplantation
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bacterial translocation in cirrhosis is increased due to structural
changes of the intestinal mucosa, including dilatation of
intercellular space and vascular congestion as well as mucosal
oxidative damage [20], and probably these structural changes
also contribute to a decreased barrier function during the
recovery phase of the gut post transplantation.
As an intracellular receptor NOD2 (nucleotide-binding
oligomerization domain containing 2) recognizes bacterial
peptidoglycans. This receptor is present in macrophages,
dendritic cells and certain intestinal epithelial cells, including
Paneth cells, and is known to play an important role in the
innate immunity. The three NOD2 variants R702W, G908R,
3020insC are all located in the coding region of NOD2 and lead
to an altered amino acid sequence, either due to non-
synonymous SNPs that results in amino acid exchanges or
through an insertion that results in a frame-shift mutation.
Mutations in NOD2 hence lead to a decreased activation of the
NK-κB pathway upon stimulation by bacterial peptidoglycans
[8,9]. NOD2 is also involved in modulation of Toll-like receptor
(TLR) signaling [21], and regarding this latter the recipient
TLR2 R753Q variant has also been associated with
presentation with septic shock and infection recurrence with
gram-positive bacterial infections after OLT [22]. The
observation that this NOD2 R702W variant is associated with
CSI after OLT independently from the lectin-binding
complement activation system also indicates that there might
be an interplay between these antibacterial pathways which
merits further functional studies.
Our findings complement the earlier identification of NOD2
being a risk factor in multiple infectious conditions and
transplantation related complications. NOD2 has, for instance,
been reported to be associated with increased sepsis-related
mortality in patients admitted to an Intensive Care Unit [10].
Another recent study reported an increased risk of
spontaneous bacterial peritonitis (SBP) in cirrhotic patients
carrying NOD2 variants accompanied by a reduced patient
survival time after SBP [11]. The same group also reported an
increased susceptibility towards SBP in patients carrying TLR2
polymorphisms [23]. In transplant literature NOD2 has been
linked to increased risk of graft versus host disease and
transplant-related mortality in hematopoietic stem cell
transplantation [12,24]. However, other reports could not
confirm these results [25]. In kidney transplantation mutated
NOD2 haplotypes are associated with higher rates of death
with functioning graft, but not with rejection and graft failure
[13]. Fishbein et al. found that Crohn’s disease-associated
NOD2 variants were associated with decreased graft and
patient survival after small bowel transplantation [26]. Other
studies on small bowel transplantation were inconsistent [27],
although one study confirmed the R702W variant, the same
variant that was related to CSI in the current study, was
associated with early rejection and decreased patient survival
[28].
There is an increasing interest in the use of biomarkers as
predictors for outcome in solid organ transplantation. Various
studies tried to estimate or predict the occurrence of rejection
and chronic allograft damage by correlating genomic,
transcriptomic and proteomic information from donor and
recipient with clinical phenotypes. Genomic analysis, for
instance, revealed that mutations in the innate immune system
protein Toll-like receptors in donor and/or recipient were
associated with reduced risk and severity of allograft rejection
in liver, lung and kidney [29]. With increasing knowledge about
factors involved in the risk of developing infections after liver
transplantation such biomarkers might also be a useful tool to
identify patients at risk for infections after transplantation.
Especially considering the relatively high prevalence of
bacterial infections after liver transplantation and the
considerable impact on patient morbidity and mortality such
predictors could have a considerable clinical impact. The
current study adds to that knowledge by reporting the
association of the NOD2 R702W variant in the recipient with
increased risk of bacterial infections after liver transplantation.
However, the frequencies of the three NOD2 variants we found
are low but comparable to the frequencies reported in the
literature [30] and implicates difficult assessment of association
of the variants with clinical outcomes.
In conclusion, the mutated NOD2 R702W genotype in the
recipient is associated with an increased risk of bacterial
infections after liver transplantation. This association is
independent of clinical variables and mutations in the donor
liver of the lectin complement pathway. This indicates a
possible predisposing role for this recipient NOD2 genetic risk
factor impairing the innate immune system after orthotopic liver
transplantation.
Supporting Information
Table S1.  Frequencies of NOD2 Polymorphisms in
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